For the Inventor, By the Inventor

Enter assignee name

Schlieren, Switzerland

Roche Glycart Ag

USPTO Granted Patents = 68

CIPO Patents = 10

EPO Patents = 56

Forward Citations = 1,012

Loading Chart...

Loading Chart...

89 inventors (with patents filed for the assignee):

Ekkehard Moessner (38 out of 94 patents)

Pablo Umana (37 out of 85 patents)

Christian Klein (30 out of 170 patents)

4. Ralf Hosse (25 out of 45 patents)

5. Pablo Umaña (22 out of 43 patents)

6. Peter Bruenker (17 out of 35 patents)

7. Thomas U Hofer (16 out of 28 patents)

8. Anne Freimoser-Grundschober (11 out of 23 patents)

9. Valeria G Nicolini (11 out of 16 patents)

10. Ekkehard Mössner (10 out of 15 patents)

11. Guy Georges (8 out of 71 patents)

12. Oliver Ast (8 out of 18 patents)

13. Marina Bacac (8 out of 24 patents)

14. Joël Jean-Mairet (8 out of 16 patents)

15. James E Bailey (8 out of 18 patents)

Core Competencies:

Anti-FAP Antibodies

Bispecific Antibodies

Interleukin-2 Fusion Proteins

Immunoconjugates

Antibody Glycosylation

T-Cell Activating Antigens

EGFR Binding Molecules

ADCC-Enhanced Antibodies

Mutant Interleukin-2 Polypeptides

Ocular Vascular Diseases

Humanized Antibodies

Cancer Treatment Biomarkers

68 patents: Sort by Forward Citations

1. 12286486 - Anti-FAP antibodies and methods of use (2025-04-29),

2. 11639397 - Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use (2023-05-02),

3. 11459404 - Bispecific T cell activating antigen binding molecules (2022-10-04),

4. 11365232 - Interleukin-2 fusion proteins and uses thereof (2022-06-21),

5. 11332545 - Anti-FAP antibodies and methods of use (2022-05-17),

6. 11214622 - Antibodies specific for DR5 and methods of use (2022-01-04),

7. 11130822 - Immunoconjugates (2021-09-28),

8. 11111312 - Mutant interleukin-2 polypeptides (2021-09-07),

9. 10975151 - ASPGR antibodies and uses thereof (2021-04-13),

10. 10781258 - Bispecific T cell activating antigen binding molecules (2020-09-22),

11. 10683345 - Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases (2020-06-16),

12. 10603360 - Combination IL-2 immunoconjugate therapy (2020-03-31),

13. 10577429 - Anti-FAP antibodies and methods of use (2020-03-03),

14. 10562949 - Interleukin-2 fusion proteins and uses thereof (2020-02-18),

15. 10352943 - A-fucosylation detection in antibodies (2019-07-16),

Roche Glycart AG is a subsidiary of Roche Group, a global pioneer in pharmaceuticals and diagnostics. Located in Switzerland, Roche Glycart specializes in the research and development of novel therapeutic antibodies and antibody engineering technologies. Their focus lies in providing innovative solutions for the treatment of various diseases including cancer and autoimmune disorders. With a commitment to improving patients' lives, Roche Glycart continues to advance the field of biotechnology and contribute to the advancement of healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

68 Patents

#1 in Schlieren

#212 in Switzerland

#10,453 in the World

Schlieren, Switzerland

Roche Glycart Ag

Forward Citations = 1,012

89 inventors:

Ekkehard Moessner (38 out of 94 patents)

Pablo Umana (37 out of 85 patents)

Christian Klein (30 out of 170 patents)

4. Ralf Hosse (25 out of 45 patents)

5. Pablo Umaña (22 out of 43 patents)

Please report any incorrect information to support@idiyas.com

Loading…